Background
Novartis Pharmaceuticals markets Gilenya (fingolimod), a blockbuster drug approved to treat relapsing forms of multiple sclerosis. One of Novartis’s patents — U.S. Patent No. 9,187,405 — claimed a method of treating MS by administering fingolimod at a daily oral dose of 0.5 mg, “absent an immediately preceding loading dose.” The negative limitation was important because earlier research had used a higher initial loading dose before the maintenance dose; Novartis’s patent covered the discovery that the loading dose was unnecessary and patients could start directly on the maintenance regimen.
HEC Pharm and Accord Healthcare filed Abbreviated New Drug Applications (ANDAs) to market generic versions of Gilenya, triggering a Hatch-Waxman patent lawsuit. The generic defendants argued that the “absent an immediately preceding loading dose” limitation lacked written description support under 35 U.S.C. § 112. They contended that the specification did not adequately disclose or support the concept of administering fingolimod without a loading dose in a manner that would show inventors possessed that specific invention.
The District of Delaware disagreed and held the claims valid. The generic defendants appealed to the Federal Circuit.
The Court’s Holding
The Federal Circuit affirmed. Writing for the panel, Judge Moore held that the specification adequately supported the negative limitation through clinical study data disclosed in the patent. The specification described a Phase II clinical trial in which patients received 0.5 mg fingolimod daily without any loading dose, and the data showed that the treatment was effective. This disclosure, the court reasoned, conveyed to a person skilled in the art that the inventors had actually conceived of and possessed the invention of treating MS with fingolimod at the maintenance dose alone — without the loading dose — and that this approach worked.
The court addressed the defendants’ argument that the specification never expressly stated “do not use a loading dose” in so many words. The Federal Circuit rejected this rigid approach. Written description does not require explicit recitation of every claim element; it requires that the specification demonstrate that the inventors possessed the claimed invention. Clinical data showing the maintenance-dose-only regimen was conceived, tested, and found effective was sufficient to satisfy that standard for the negative limitation at issue.
The court also rejected arguments that certain claim terms were indefinite, affirming the district court on all grounds.
Key Takeaways
- Negative claim limitations — limitations that exclude something from a claimed method or composition — can be supported by written description when the specification contains data or disclosure showing the inventors conceived and possessed the narrowed invention.
- Adequate written description does not require the specification to explicitly spell out each negative limitation; it requires the overall disclosure to demonstrate possession of what is claimed.
- Clinical trial data included in a pharmaceutical patent specification can serve as written description support, even for unconventional claim elements like the absence of a particular dosing step.
- For pharmaceutical patent drafters, including study data on alternative dosing regimens (including those omitting standard steps) can shore up written description for resulting claims.
Why It Matters
Negative claim limitations are increasingly common in pharmaceutical and biotech patents, where inventors frequently discover that a commonly used step or ingredient is unnecessary or harmful and claim inventions that omit it. Novartis v. HEC Pharm clarifies that such limitations can survive written description challenges when the patent specification includes concrete data showing the inventors actually tested and reduced to practice the claimed approach.
For Novartis, the decision protected hundreds of millions of dollars in annual Gilenya sales from generic competition. More broadly, it gives pharmaceutical innovators confidence that carefully constructed clinical trial disclosures in patent applications can support negative limitations — a tool that is valuable in drug development, where the absence of a treatment step (like a loading dose, a co-administration requirement, or a food restriction) can itself be the patentable advance.